Medicare Enrolled
Dr. Adnan Afzal, M.D.
Cardiovascular Disease · Conroe, TX
Practice pattern: Remote Monitoring— Significant remote device monitoring activity
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Afzal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Afzal? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Afzal
Dr. Adnan Afzal is a cardiovascular disease in Conroe, TX, with 19 years in practice. Based on federal Medicare data, Dr. Afzal performed 9,877 Medicare services across 3,528 unique beneficiaries.
Between the years covered by Open Payments, Dr. Afzal received a total of $14,650 from 48 pharmaceutical and/or device companies across 749 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Afzal is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 3% volume in TX$ $14,650 industry payments
Medicare Practice Summary
Medicare Utilization ↗9,877
Medicare services
Top 3% in TX for cardiovascular disease
3,528
Unique beneficiaries
$62
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~520 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 2,352 | $31 | $118 |
| Remote patient monitoring management, 20 min/month | 1,476 | $37 | $145 |
| Remote patient monitoring device, 30 days | 1,279 | $38 | $159 |
| Electrocardiogram (EKG), 12-lead | 900 | $10 | $44 |
| Office visit, established patient (30-39 min) | 660 | $93 | $378 |
| Office visit, established patient (20-29 min) | 607 | $61 | $267 |
| Regadenoson injection (Lexiscan) for heart stress test | 396 | $43 | $70 |
| Echocardiogram, transthoracic | 202 | $138 | $502 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 170 | $36 | $650 |
| Remote pacemaker/defibrillator monitoring, 90 days | 167 | $16 | $68 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 158 | $50 | $209 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 155 | $14 | $54 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 139 | $311 | $1,612 |
| Remote pacemaker monitoring, 90 days | 132 | $21 | $88 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 118 | $28 | $400 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 96 | $20 | $77 |
| Ultrasound of both sides of head and neck blood flow | 91 | $138 | $488 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 85 | $331 | $1,165 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 68 | $1,075 | $3,215 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 65 | $138 | $561 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 58 | $91 | $356 |
| Initial hospital admission, moderate complexity | 56 | $89 | $374 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 46 | $52 | $224 |
| Hospital follow-up visit, moderate complexity | 46 | $59 | $209 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 40 | $832 | $3,292 |
| New patient office visit, complex (60-74 min) | 40 | $142 | $646 |
| New patient office visit (45-59 min) | 39 | $108 | $485 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 34 | $27 | $110 |
| Programming of dual lead pacemaker system | 29 | $57 | $246 |
| Ultrasound of leg arteries or artery grafts | 28 | $185 | $722 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 27 | $639 | $2,609 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 26 | $18 | $75 |
| Cardiac catheterization | 23 | $189 | $840 |
| Office visit, established patient (10-19 min) | 23 | $38 | $165 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 18 | $10 | $149 |
| Hospital follow-up visit, high complexity | 17 | $93 | $297 |
| New patient office visit (30-44 min) | 11 | $85 | $327 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.9% high complexity
10.0% medium
84.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,650
Total received (2018-2024)
Avg $2,093/year across 7 years
Top 24% in TX for cardiovascular disease
48
Companies
749
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,650 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,712
2023$2,833
2022$2,061
2021$1,959
2020$1,159
2019$2,158
2018$2,769
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$2,049
Amgen Inc.
$1,898
Abbott Laboratories
$1,395
Medtronic Vascular, Inc.
$1,164
Boston Scientific Corporation
$1,084
Medtronic, Inc.
$895
BIOTRONIK INC.
$763
Janssen Pharmaceuticals, Inc
$444
E.R. Squibb & Sons, L.L.C.
$400
Boehringer Ingelheim Pharmaceuticals, Inc.
$382
Esperion Therapeutics, Inc.
$315
AstraZeneca Pharmaceuticals LP
$303
Merck Sharp & Dohme LLC
$254
Impulse Dynamics (USA) Inc.
$249
SANOFI-AVENTIS U.S. LLC
$246
PFIZER INC.
$237
Gilead Sciences, Inc.
$235
BOSTON SCIENTIFIC CORPORATION
$234
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$230
Biosense Webster, Inc.
$227
Amarin Pharma Inc.
$206
Chiesi USA, Inc.
$204
Venclose Inc.
$196
Baxter Healthcare
$142
Tactile Systems Technology Inc
$128
Regeneron Healthcare Solutions, Inc.
$120
HeartFlow, Inc.
$98
CVRx, Inc.
$95
Philips Electronics North America Corporation
$63
Bayer HealthCare Pharmaceuticals Inc.
$46
ARBOR PHARMACEUTICALS, INC.
$42
Bardy Diagnostics, Inc.
$27
Astellas Pharma US Inc
$25
Braemar Manufacturing, LLC
$24
AGEPHA Pharma FZ LLC
$23
Kestra Medical Technology Services, Inc.
$22
Lexicon Pharmaceuticals, Inc.
$19
ZOLL Circulation Inc
$19
Kowa Pharmaceuticals America, Inc.
$17
Philips North America LLC
$17
Cleerly, Inc.
$16
AngioDynamics, Inc.
$16
Cook Medical LLC
$15
Bard Peripheral Vascular, Inc.
$15
Resmed Corp
$15
Allergan Inc.
$14
Siemens Medical Solutions USA, Inc.
$14
Actelion Pharmaceuticals US, Inc.
$11
Top 3 companies account for 36.5% of total payments
Associated products mentioned in payments ›
(CK4) MCOT · AMPLATZER AMULET · AMPLATZER TALISMAN · AirMini · Assure WCD · Azure · BIOMONITOR · BRILINTA · BYSTOLIC · Barostim Neo System · BodyGuardian · CAMZYOS · CARDIOMEMS · CHANTIX · CLEVIPREX · CONFIRM RX · COREVALVE EVOLUT R · Cardiac Monitoring Suite · CareLink · Carnation Ambulatory Monitor · Claria MRI · Cleerly Ischemia · ClosureFast · Confirm Rx · CorPath GRX · Corlanor · DIAMONDBACK PERIPHERAL · ELIQUIS · ENTRESTO · EVRSF · Edarbi · EnSite Precision Cardiac Mapping System · Ensite Cardiac Mapping System · FARXIGA · FFRct · FLEXITOUCH · Flexitouch Plus · GENERAL - THROMBECTOMY · GENERAL - VASCULAR INTERVENTION · HawkOne · HeartMate 3 Left Ventricular Assist Device · Hillrom - Carnation Ambulatory Monitor · IN.PACT Admiral · Ingenia 1.5T R4 · Inpefa · JARDIANCE · KENGREAL · Kerendia · LEQVIO · LEXISCAN · LODOCO · LOKELMA · LUX-Dx Insertable Cardiac Monitor · LifeVest · Livalo · MERLIN@HOME · MULTAQ · Mitra Clip system · NAVITOR · NEXLETOL · OCTARAY MAPPING CATHETER · OPSUMIT · OPTIMIZER · Optimizer · Optimizer Smart System · PRADAXA · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Proclaim IPG · QUADRA ASSURA · RESONATE · REVEAL LINQ · Ranexa · Repatha · THORATEC HEARTMATE 3 LVAS IMPLANT KIT · Temperature Management System · TurboHawk · VENASEAL · VERQUVO · Vascepa · VenaCure 1470 Pro · VenaSeal · Verquvo · ViewFlex Xtra ICE Catheter · Visia AF · WATCHMAN · WATCHMAN Access System · WATCHMAN FLX · XARELTO · ZILVER PTX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $148 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
85
Per 100K population
13.0
County median income
$97,266
Nearest hospital
HCA HOUSTON HEALTHCARE CONROE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Afzal is a remote monitoring specialist, with above-average Medicare volume (top 3% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Afzal experienced with management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes?
Based on Medicare claims data, Dr. Afzal performed 2,352 management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Afzal receive payments from pharmaceutical companies?
Yes. Dr. Afzal received a total of $14,650 from 48 companies across 749 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Afzal's costs compare to other cardiovascular diseases in Conroe?
Dr. Afzal's average Medicare payment per service is $62. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Afzal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Conroe
Browse cardiovascular diseases in Conroe ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc..
By company
Abbott Laboratories Payments to Doctors
See all physicians who received payments from Abbott Laboratories.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology